-
Je něco špatně v tomto záznamu ?
Survival after Radical Prostatectomy versus Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer
F. Chierigo, M. Wenzel, C. Würnschimmel, RS. Flammia, B. Horlemann, Z. Tian, F. Saad, FKH. Chun, M. Graefen, M. Gallucci, SF. Shariat, G. Mantica, M. Borghesi, N. Suardi, C. Terrone, PI. Karakiewicz
Jazyk angličtina Země Spojené státy americké
Typ dokumentu srovnávací studie, časopisecké články
- MeSH
- analýza přežití MeSH
- brachyterapie statistika a číselné údaje MeSH
- hodnocení rizik statistika a číselné údaje MeSH
- kalikreiny krev MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádory prostaty krev diagnóza mortalita terapie MeSH
- program SEER MeSH
- prostata patologie účinky záření chirurgie MeSH
- prostatektomie statistika a číselné údaje MeSH
- prostatický specifický antigen krev MeSH
- retrospektivní studie MeSH
- rizikové faktory MeSH
- senioři MeSH
- staging nádorů MeSH
- stupeň nádoru MeSH
- tendenční skóre MeSH
- věkové faktory MeSH
- výsledek terapie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- Publikační typ
- časopisecké články MeSH
- srovnávací studie MeSH
PURPOSE: Our goal was to compare cancer-specific mortality (CSM) rates between radical prostatectomy (RP) vs external beam radiotherapy (EBRT) in National Comprehensive Cancer Network© (NCCN©) high risk (HR) patients, as well as in Johns Hopkins University (JH) HR and very high risk (VHR) subgroups. MATERIALS AND METHODS: Within the Surveillance, Epidemiology, and End Results database (2010-2016), we identified 24,407 NCCN HR patients, of whom 10,300 (42%) vs 14,107 (58%) patients qualified for JH HR vs VHR, respectively. Overall, 9,823 (40%) underwent RP vs 14,584 (60%) EBRT. Cumulative incidence plots and competing-risks regression addressed CSM after 1:1 propensity score matching (according to age, prostate specific antigen, clinical T and N stages, and biopsy Gleason score) between RP and EBRT patients. All analyses addressed the combined NCCN HR cohort, as well as in JH HR and JH VHR subgroups. RESULTS: In the combined NCCN HR cohort 5-year CSM rates were 2.3% for RP vs 4.1% for EBRT and yielded a multivariate hazard ratio of 0.68 (95% CI 0.54-0.86, p <0.001) favoring RP. In VHR patients 5-year CSM rates were 3.5% for RP vs 6.0% for EBRT, yielding a multivariate hazard ratio of 0.58 (95% CI 0.44-0.77, p <0.001) favoring RP. Conversely, in HR patients no significant difference was recorded between RP vs EBRT (HR 0.7, 95% CI 0.39-1.25, p=0.2). CONCLUSIONS: Our data suggest that RP holds a CSM advantage over EBRT in the combined NCCN HR cohort, and in its subgroup of JH VHR patients.
Department of Surgical and Diagnostic Integrated Sciences University of Genova Genova Italy
Department of Urology 2nd Faculty of Medicine Charles University Prague Czech Republic
Department of Urology Comprehensive Cancer Center Medical University of Vienna Vienna Austria
Department of Urology University Hospital Frankfurt Frankfurt am Main Germany
Department of Urology University of Texas Southwestern Dallas Texas
Departments of Urology Weill Cornell Medical College New York New York
Martini Klinik Prostate Cancer Center University Hospital Hamburg Eppendorf Hamburg Germany
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22011179
- 003
- CZ-PrNML
- 005
- 20220506130055.0
- 007
- ta
- 008
- 220425s2022 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1097/JU.0000000000002250 $2 doi
- 035 __
- $a (PubMed)34555930
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Chierigo, Francesco $u Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, Genova, Italy $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada $1 https://orcid.org/0000000173570758
- 245 10
- $a Survival after Radical Prostatectomy versus Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer / $c F. Chierigo, M. Wenzel, C. Würnschimmel, RS. Flammia, B. Horlemann, Z. Tian, F. Saad, FKH. Chun, M. Graefen, M. Gallucci, SF. Shariat, G. Mantica, M. Borghesi, N. Suardi, C. Terrone, PI. Karakiewicz
- 520 9_
- $a PURPOSE: Our goal was to compare cancer-specific mortality (CSM) rates between radical prostatectomy (RP) vs external beam radiotherapy (EBRT) in National Comprehensive Cancer Network© (NCCN©) high risk (HR) patients, as well as in Johns Hopkins University (JH) HR and very high risk (VHR) subgroups. MATERIALS AND METHODS: Within the Surveillance, Epidemiology, and End Results database (2010-2016), we identified 24,407 NCCN HR patients, of whom 10,300 (42%) vs 14,107 (58%) patients qualified for JH HR vs VHR, respectively. Overall, 9,823 (40%) underwent RP vs 14,584 (60%) EBRT. Cumulative incidence plots and competing-risks regression addressed CSM after 1:1 propensity score matching (according to age, prostate specific antigen, clinical T and N stages, and biopsy Gleason score) between RP and EBRT patients. All analyses addressed the combined NCCN HR cohort, as well as in JH HR and JH VHR subgroups. RESULTS: In the combined NCCN HR cohort 5-year CSM rates were 2.3% for RP vs 4.1% for EBRT and yielded a multivariate hazard ratio of 0.68 (95% CI 0.54-0.86, p <0.001) favoring RP. In VHR patients 5-year CSM rates were 3.5% for RP vs 6.0% for EBRT, yielding a multivariate hazard ratio of 0.58 (95% CI 0.44-0.77, p <0.001) favoring RP. Conversely, in HR patients no significant difference was recorded between RP vs EBRT (HR 0.7, 95% CI 0.39-1.25, p=0.2). CONCLUSIONS: Our data suggest that RP holds a CSM advantage over EBRT in the combined NCCN HR cohort, and in its subgroup of JH VHR patients.
- 650 _2
- $a věkové faktory $7 D000367
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a brachyterapie $x statistika a číselné údaje $7 D001918
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a kalikreiny $x krev $7 D007610
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a stupeň nádoru $7 D060787
- 650 _2
- $a staging nádorů $7 D009367
- 650 _2
- $a tendenční skóre $7 D057216
- 650 _2
- $a prostata $x patologie $x účinky záření $x chirurgie $7 D011467
- 650 _2
- $a prostatický specifický antigen $x krev $7 D017430
- 650 _2
- $a prostatektomie $x statistika a číselné údaje $7 D011468
- 650 _2
- $a nádory prostaty $x krev $x diagnóza $x mortalita $x terapie $7 D011471
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a hodnocení rizik $x statistika a číselné údaje $7 D018570
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a program SEER $7 D018426
- 650 _2
- $a analýza přežití $7 D016019
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Wenzel, Mike $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada $u Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany
- 700 1_
- $a Würnschimmel, Christoph $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada $u Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany
- 700 1_
- $a Flammia, Rocco Simone $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada $u Department of Maternal-Child and Urological Sciences, Sapienza Rome University, Policlinico Umberto I Hospital, Rome, Italy
- 700 1_
- $a Horlemann, Benedikt $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada
- 700 1_
- $a Tian, Zhe $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada
- 700 1_
- $a Saad, Fred $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada
- 700 1_
- $a Chun, Felix K H $u Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany
- 700 1_
- $a Graefen, Markus $u Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany
- 700 1_
- $a Gallucci, Michele $u Department of Maternal-Child and Urological Sciences, Sapienza Rome University, Policlinico Umberto I Hospital, Rome, Italy
- 700 1_
- $a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Departments of Urology, Weill Cornell Medical College, New York, New York $u Department of Urology, University of Texas Southwestern, Dallas, Texas $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic $u Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia $u Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan
- 700 1_
- $a Mantica, Guglielmo $u Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, Genova, Italy
- 700 1_
- $a Borghesi, Marco $u Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, Genova, Italy
- 700 1_
- $a Suardi, Nazareno $u Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, Genova, Italy
- 700 1_
- $a Terrone, Carlo $u Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, Genova, Italy
- 700 1_
- $a Karakiewicz, Pierre I $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada
- 773 0_
- $w MED00003040 $t The Journal of urology $x 1527-3792 $g Roč. 207, č. 2 (2022), s. 375-384
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34555930 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220425 $b ABA008
- 991 __
- $a 20220506130047 $b ABA008
- 999 __
- $a ok $b bmc $g 1788998 $s 1162377
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 207 $c 2 $d 375-384 $e 20210924 $i 1527-3792 $m The Journal of urology $n J Urol $x MED00003040
- LZP __
- $a Pubmed-20220425
